Schroder Investment Management Group Purchases 11,739 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Schroder Investment Management Group increased its position in Ascendis Pharma A/S (NASDAQ:ASND) by 14.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,728 shares of the biotechnology company’s stock after buying an additional 11,739 shares during the period. Schroder Investment Management Group owned 0.15% of Ascendis Pharma A/S worth $12,656,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nomura Asset Management Co. Ltd. increased its stake in shares of Ascendis Pharma A/S by 13.9% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 20,506 shares of the biotechnology company’s stock worth $2,823,000 after purchasing an additional 2,506 shares during the last quarter. New Age Alpha Advisors LLC bought a new stake in Ascendis Pharma A/S in the fourth quarter worth $507,000. NEOS Investment Management LLC boosted its holdings in Ascendis Pharma A/S by 43.1% in the fourth quarter. NEOS Investment Management LLC now owns 19,040 shares of the biotechnology company’s stock worth $2,621,000 after purchasing an additional 5,736 shares in the last quarter. BIT Capital GmbH increased its position in Ascendis Pharma A/S by 8.1% during the fourth quarter. BIT Capital GmbH now owns 73,990 shares of the biotechnology company’s stock worth $10,186,000 after buying an additional 5,569 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Ascendis Pharma A/S by 94.4% during the fourth quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company’s stock valued at $10,659,000 after buying an additional 37,593 shares in the last quarter.

Ascendis Pharma A/S Stock Down 1.4 %

Ascendis Pharma A/S stock opened at $150.09 on Friday. The business has a 50 day moving average price of $146.11 and a two-hundred day moving average price of $138.05. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37. The stock has a market cap of $9.11 billion, a price-to-earnings ratio of -21.14 and a beta of 0.61.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ASND. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, February 25th. UBS Group initiated coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.